US court blocks terminally ill patient from access to experimental drug
This article was originally published in SRA
Executive Summary
A US appeals court has ruled in favour of a pharmaceutical company, stating that the company cannot be forced to offer an experimental drug to a terminally ill patient outside the clinical trial process1,2. The court decision reverses an earlier controversial decision by a district court, which created a stir among pharma companies when it ordered PTC Therapeutics - against its objections - to provide the patient access to its investigational drug, PTC124.